Treating lupus in the kidney: where are we now, and where are we going?
Kidney involvement is a frequent and dreaded consequence of systemic lupus erythematosus. While historically this condition was devastatingly morbid, over the past thirty years an improved understanding of the disease's pathobiology has accompanied increasingly effective treatment regimens that have dramatically improved the prognosis for affected patients. Induction and maintenance of remission can now be obtained in the majority of patients, although at least 20-30% may be refractory to treatment. What's more, the standard drugs in use for lupus nephritis remain fairly broad immunosuppressants, and carry notable risks and side effects. Recent years have witnessed an explosion in the number of novel immunomodulatory drugs being developed, with increasingly specific targets of action in the immune system. These molecules hold promise for a range of autoimmune disorders, including lupus nephritis, and several are already being actively investigated for that purpose. Here we review the current state of the art in the treatment of lupus nephritis, highlight the limits of standard treatments, and discuss the most promising of the novel therapies coming down the pipeline.
Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York 10032, USA.
Pietro A A
PA
Canetta
Andrew S
AS
Bomback
Jai
J
Radhakrishnan
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007668:Kidney / Q000276:immunology / Q000473:pathology*; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000276:immunology
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents